Skip to main content
. 2014 Oct 30;10(11):2036–2052. doi: 10.4161/auto.34398

Figure 8.

Figure 8.

Human breast cancers with low BECN1 expression and an activated WNT pathway gene signature have poor prognosis. (A–D) Kaplan-Meier curves and GSEA for breast tumors displaying an activated WNT pathway gene signature and stratified for BECN1 expression (see Methods). (A) Disease-free survival for patients with breast cancers annotated in the Sabatier cohort (P 7.2 × 10−5). (B) Disease-free survival for patients with ERBB2-negative breast cancers annotated in the Hatzis cohort (P 2.7 × 10−3). Gene expression analysis comparison in (C) the Sabatier cohort and (D) the Hatzis cohort reveals that breast cancers with low BECN1 and an activated WNT pathway gene signature are primarily triple-negative, have basal-like characteristics, and display TNFRSF11A pathway activation and higher CTNNB1. P values were calculated by the Fischer exact test (see Materials and Methods). (E) Model for the cooperation between monoallelic BECN1 loss and WNT pathway activation in mammary tumorigenesis. *P < 0.05, **P < 0.01, ***P < 0.001.